Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | BRS3 | P32247 | 1/20 | 0.38 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
| ▸ | ATR | Q13535 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | LATS1 | O95835 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propyne SCHEMBL6530506 | 0.97 | NAMPT (0.42) | NAMPTCYP17A1RAB9ABRS3METAP1 | |
| SCHEMBL8313717 | 0.86 | NAMPT (0.45) | NAMPTCYP17A1RAB9ABRS3METAP1 | |
| SCHEMBL26828150 | 0.85 | NAMPT (0.43) | NAMPTCYP17A1RAB9AMETAP1LMNA | |
| SCHEMBL21566054 | 0.83 | KDM4E (0.40) | NAMPTCYP17A1RAB9ABRS3METAP1 | |
| SCHEMBL19255631 | 0.81 | CYP1A2 (0.46) | NAMPT | |
| SCHEMBL18522430 | 0.81 | NAMPT (0.50) | NAMPTCYP17A1RAB9ABRS3METAP1 | |
| SCHEMBL19211781 | 0.80 | KDM4C (0.39) | NAMPT | |
| SCHEMBL2107971 | 0.79 | NAMPT (0.48) | NAMPTCYP17A1RAB9ABRS3METAP1 | |
| SCHEMBL3666785 | 0.79 | NAMPT (0.48) | NAMPTCYP17A1RAB9ABRS3METAP1 | |
| SCHEMBL5777673 | 0.78 | NAMPT (0.45) | NAMPTCYP17A1RAB9ABRS3METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9657012-B2 | FAAH inhibitors | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| EP-2655356-B1 | FAAH INHIBITORS | IRONWOOD PHARMACEUTICALS INC (US) | 2016-08-03 | — | — | EP | disclosed |
| US-20150175599-A1 | FAAH Inhibitors | IRONWOOD PHARMACEUTICALS, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-8741897-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741897-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741897-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2014-06-03 | — | — | US | disclosed |
| EP-2655356-A1 | FAAH INHIBITORS | Ironwood Pharmaceuticals, Inc. (US) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012088469-A1 | FAAH INHIBITORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| EP-1673088-A1 | 1,1,1- TRIFLUORO-4-PHENYL-4-METHYL-2-(1H-PYRROLO¬2,3-C|PYRIDIN-2-YLMETHYL)PENTAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS GLUCOCORTICOID LIGANDS FOR THE TREATMENT OF INFLAMMATORY DISEASES AND DIABETES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005121141-A1 | PYRROLOPYRIDINE DERIVATIVES AND USE THEREOF FOR TREATING DISEASES MEDIATED BY PROSTAGLANDIN D2 (PGD2) | OXAGEN LIMITED (GB) | 2005-12-22 | — | — | WO | disclosed |
| US-20050176706-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-08-11 | — | — | US | disclosed |
| WO-2005030213-A1 | 1,1,1-TRIFLUORO-4-PHENYL-4-METHYL-2-(1H-PYRROLO | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176706-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | NR3C1, NR3C2, MC2R | NAMPT 3568/4885CYP17A1 51/4885RAB9A 3602/4885 |
| US-20150175599-A1 | FAAH Inhibitors | FAAH, FAAH2, ASAH1 | NAMPT 932/4885CYP17A1 1118/4885RAB9A 1384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.